Diabetes, COVID-19 and DPP-4

The aim fof this large multicentric study published in Diabetes, Obesity and Metabolism was toinvestigate the association between routine use of dipeptidyl peptidase-4 (DPP-4) inhibitors and the severity of coronavirus disease 2019 (COVID-19) infection in patient with type 2 diabetes.

Results support the safety of DPP-4 inhibitors for diabetes management during the COVID-19 pandemic and they should not be discontinued.